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In order to address whether increased levels of movement output variability indicate pathological performance, we
systematically reviewed and synthesized meta-analysis data on healthy and pathological motor behavior. After
screening up to 24’000 reports from four databases, 85 studies were included containing 2409 patients and 2523
healthy asymptomatic controls. The optimal thresholds of variability with uncertainty boundaries (in %
Coefficient of Variation ± Standard Error) were estimated in 7 parameters: stride time (2.34 ± 0.21), stride
length (2.99 ± 0.37), step length (3.34 ± 0.84), swing time (2.94 ± 0.60), step time (3.35 ± 0.23), step
width (15.87 ± 1.86), and dual-limb support time (6.08 ± 2.83). All spatio-temporal parameters exhibited a
positive effect size (pathology led to increased variability) except step width variability (Effect Size = −0.21).
By objectively benchmarking thresholds for pathological motor variability also presented through a case-study,
this review provides access to movement signatures to understand neurological changes in an individual that are
apparent in movement variability. The comprehensive evidence presented now qualifies stride time variability
as a movement biomarker, endorsing its applicability as a viable outcome measure in clinical trials.

1. Introduction

Movement Variability (MoV - (Stergiou et al., 2006; Herzfeld and
Shadmehr, 2014)).
The ability to walk in a stable manner declines with age and pathology, adversely affecting health-related quality of life (Netuveli and
Blane, 2008; Seidler et al., 2010). Furthermore, movement deficits require individuals to perform activities near their maximal effort (Singh
et al., 2012; Aagaard et al., 2010; Chandler et al., 1998), thus continually challenging them physically (but also cognitively (Beauchet
et al., 2011; Hamilton et al., 2009)) and, in many cases, leading to
adverse events such as injurious falling. Recent evidence shows that
elderly adults produce repetitive movements such as walking with
greater MoV, possibly due to the loss in strength and flexibility (Kang
and Dingwell, 2008) as well as the decline in walking speed (Chien
et al., 2015). Interestingly, MoV is even greater in individuals that are
at a high risk of falling (Hamacher et al., 2011; König et al., 2014b), or
suffer from neurological disorders affecting motor function (hereinafter
referred to as “movement disorders”) such as Parkinson’s disease (PD),
Multiple Sclerosis, or Huntington’s disease (König et al., 2016a;

The effective performance of activities of daily living such as
standing, walking or reaching is fundamental to leading an independent
life. Walking specifically, is an essential locomotor activity that requires
effective regulation between central and peripheral nervous, and musculoskeletal system resources allowing us to synergize the movement of
limbs both spatially (inter-limb coordination) and temporally (rhythmicity
– constancy in step repetitions), such that we can maintain our balance
(regulation of the centre of mass over the base of support) (Clark, 2015;
Plotnik and Hausdorff, 2008; Bruijn and van Dieen, 2018). In addition,
these resources are needed to negotiate obstacles in the environment
(obstacle avoidance) and to respond to perturbations to the moving
body (Kovacs, 2005; Song and Geyer, 2017). Due to the continuous
regulation of these neural resources, as well as the noise inherently
present in both sensory and motor signals (Singh et al., 2012; König
et al., 2014a; Jones et al., 2002; Churchland et al., 2006), motor output
fluctuates around a target or desired level, termed motor output or
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Hausdorff et al., 2001; Hausdorff, 2005; Moe-Nilssen et al., 2010).
It is likely that an optimal window of MoV characterises asymptomatic individuals, and differentiates healthy from pathological movement function (Singh et al., 2012; Stergiou et al., 2006; König et al.,
2016b; Stergiou and Decker, 2011; Rosenblatt et al., 2014). In general,
below this window, movement is likely to become rigid (system with
limited flexibility to adjust to internal and external perturbations),
while MoV above the optimum would bring the system closer to its
limits of stability (generally provided by the feet in contact with the
ground that form the base-of-support – see (Hof et al., 2007) for details), with both extremes indicating deficits in movement performance
(Stergiou and Decker, 2011). Such an interpretation might appear in
line with contemporary theoretical frameworks (cf. proposed by
(Todorov, 2004), but also confirmed by (Cusumano and Dingwell,
2013)), which hypothesize that movement tasks are likely adapted and
executed (i.e. the level that one should aim for (Todorov, 2004)) by
optimizing accuracy, while requiring minimal control effort. The
threshold probed within this study however, is conceptually different in
that it reflects an optimal boundary identified across multiple studies
that differentiates healthy from pathological gait. Such a threshold
would allow the possible use of MoV as an effective biomarker for assessing an individual’s neuro-motor status. A comprehensive knowledge
of MoV with clear definitions for asymptomatic task performance in
both temporal and spatial domains could allow different metrics of
variability to be established as intrinsic features of performance (signatures) to associate an individual’s quality of movement with their
underlying neural status. In essence, by identifying the optimal
thresholds for benchmarking motor signatures, we envisage prioritising
and formalising potentially useful movement-based biomarkers for neurological disorders (Shipitsin et al., 2014; Strimbu and Tavel, 2010). As
such, a well-defined biomarker, or combination thereof, can address the
persistent clinical need for early identification of movement disorders
(screening) as well as for evaluating the effectiveness of therapies for
returning individual patients to some level of independent living.
In a previous systematic review (König et al., 2016b), we investigated the thresholds between healthy asymptomatic and pathological magnitudes of task variability, and concluded that, for the parameter “variability of stride time” (STV; evaluated as the coefficient of
variation, CV of stride time), upper thresholds of 2.6%CV discriminated
pathological from healthy adults performance. Furthermore, 1.1%CV
was identified as the lower threshold for healthy variability in adults.
Although the systematic review approach was comprehensive, a very
large sample of clinical trials, each consisting of a suitable number of
subjects, is clearly needed in order to better estimate the true value of
the boundaries. Until then, such a pool of information will neither be
reliable nor robust, meaning that the inclusion of any further clinical trial
data would have sufficient relative weight to influence the existing
evidence on optimal levels of variability. Therefore, it is critical to
determine methods that are able to absorb the changes such that the
estimated boundary levels remain robust and meaningful in light of
additional evidence. One such approach involving the estimation of
probabilistic thresholds has been proposed previously in other domains,
but never used in the clinical context of movement signatures (Xu and
Gupta, 2005). As a result, due to the growing recognition of metrics of
MoV for assessment in clinical settings, a full and complete study
evaluating thresholds between healthy asymptomatic and pathological
task variability, is timely.
The selective effects of movement disorders such as PD on different
neurological structures (consequently impairments may also be variable) highlight the importance of holistically understanding the interplay between various locomotor characteristics that are critical during
walking (König et al., 2016a). However, due to the conventional subjective approach of pre-selecting parameters in a somewhat arbitrary
manner (e.g. STV is reported far more than any other spatio-temporal
parameter in the literature (König et al., 2016b), possibly due to its ease
of measurement), the complex interactions between multiple different

features of walking remain largely unexplored. Such subjective practices therefore hinder an accurate characterization of movement deficits
in both clinical cohorts and on an individual basis. Thus, an understanding of how multiple signatures of gait are regulated would lay the
foundations for unravelling the neuromuscular mechanisms that are
involved in not only walking, but also movement in general (Galna
et al., 2013; Dingwell and Cusumano, 2000; Lord et al., 2011). With a
vision to distinguish healthy asymptomatic from pathological gait
performance in a holistic manner, we therefore aim to broaden our
knowledge of optimal windows of variability (originally investigated
only for stride time (König et al., 2016b)) by estimating the optimal
thresholds for all commonly reported characteristics of walking.
The aim of this review was therefore to firstly provide current stateof-the-art and reliable evidence on magnitude of MoV in healthy
walking behaviour, but also to exploit a probabilistic approach for
improving the robustness of the optimum window of MoV. Finally, this
paper presents a case study involving a statistical model for investigating motor deficits in PD patients using the optimum thresholds
identified in the review, including preliminary data from a retrospective case-control study.
2. Methods
2.1. Search strategy and study selection
The literature search and selection strategy (Supp. Methods 1) in the
original systematic review (König et al., 2016b) was maintained in this
study in order to extend the search for articles published after June
2014 until June 2018. Four databases: PubMed, Web of Science, Embase and Ebsco were comprehensively searched to include only studies
in which continuous measures of variability during straight line
walking were collected in both healthy asymptomatic adults and patients with a neurological disorder. The inclusion criteria for the studies
was: 1) Outcome measure - inter-cycle variability of gait measures (e.g.
step length, stance time) expressed by percentage coefficient of variation, calculated as the ratio of the standard deviation to the mean, 2)
Participants - cohort of healthy adults and a cohort of patients with a
neurological pathology, and 3) Task - walking on a treadmill or overground at a comfortable or self-selected walking speed. The search was
further restricted to peer reviewed articles published in the English
language. An exhaustive list of exclusion criteria is presented as supplementary material (Supp. Methods 2. Exclusion criteria). Two of the
authors (DKR and MG) performed the literature search and screened the
studies at each stage of the review; any disagreement was resolved by
consensus (together with NBS). The study was performed in line with
the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA, see Fig. 1) and the PRISMA checklist is provided as
supplementary material. The literature search identified 11,111 potentially relevant articles. After the removal of duplicates (n = 2384)
and articles rejected based on title or abstract (n = 8543), 184 articles
were included for full text screening. During this process, a further 163
articles were excluded. Finally, 21 studies were included containing a
total sample of 752 patients and 608 healthy asymptomatic participants
over and above the 1657 patients and 1915 healthy asymptomatic
participants from the original study (König et al., 2016b). The characteristics of all included studies is presented in a supplementary table
(Supp. Table 1). Screening of all the articles were performed within the
EPPI-Reviewer 4 software.
2.2. Risk of bias assessment
Two authors (DKR and NBS) independently assigned the risk of bias
quality scores to the studies with the use of the MINORS tool. Each
study was assessed as having high, unclear or low risk of bias on all
items (scored from 0 to 2 respectively with an ideal global score of 18)
included in the original checklist (three items: Unbiased Assessment of
25
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Fig. 1. PRISMA flow diagram showing the selection and exclusion of studies in this meta-analysis.

the Study Endpoint, Follow-up period appropriate to the aim of the
study, and Loss to follow up less than 5% were considered irrelevant
and were excluded). Any discrepancies between reviewers were resolved through consensus. The results are presented in a supplementary
table (Supp. Table 2).

linear combination of the predictor variable (CV gait parameter) and
the study index (random effects). As the means of the healthy asymptomatic and pathological groups for a particular walking parameter
originating from the same study could be correlated to each other due
to the inherent study design and experimental protocol, a mixed-effects
model was used to account for the random effect of the paired data
(healthy asymptomatic vs. pathological) within each included study
and also accounting for heterogeneity in meta-analysis.
The logistic model (with random effect for the study index) is given by:

2.3. Data analysis and synthesis
We used measures of variability of spatio-temporal parameters of
walking reported through coefficient of variation (CV) for both healthy
asymptomatic and pathological cohorts. An effect size (ES - the difference between the means of the pathological and healthy asymptomatic
control groups over the pooled standard deviation, which was additionally corrected for sample size to provide Hedges' g) for each study
was used to express the difference between cohorts in a standardised
manner. The group averages for each gait parameter from all studies
were then combined by calculating a pooled effect size using standard
error as a weighting factor (in order to minimize the risk of overestimation). Heterogeneity among the included studies was assessed
and interpreted using I2 statistics (according to the Cochrane guidelines
(Higgins et al., 2011)). Additionally, potential publication bias was
assessed through visual inspection of the funnel plot with effect sizes
and standard error of the effect estimate. In order to estimate the upper
boundary of the performance window, all studies that exhibited a positive ES were selected for the logistic regression. Similarly, studies that
revealed a negative ES formed the basis for estimating the lower
boundary (König et al., 2016b).
A generalized linear mixed model fit using maximum likelihood
criteria (with Laplace approximation to integrate the likelihood function (Handayani et al., 2017)) was used to model the log odds of the
binary outcome (0 for healthy asymptomatic, 1 for pathological) as a

log

pi
1

pi

= B0 + B1 * x i+Ui

(1)

where pi is the probability that the observation belonged to a particular
cohort given the predictor variable, x i (gait parameter), and the study
index, Ui ; B0 and B1 are coefficient estimates of the regression model
estimated using maximum likelihood (see Supp. Figures. 1–7). Finally,
in order to test whether the model with the predictor variable (model
with the alternate hypothesis wrt coefficient B1) fits significantly better
than a null model (model with the null hypothesis wrt B1), we evaluated
Bayes Factor using ΔBIC (where ΔBIC = BICH1 – BICH0 and BIC is the
Bayesian Information Criterion - please refer to (Jarosz and Wiley,
2014)).
The discriminatory accuracy of our model was assessed using the
receiver operating characteristic (ROC) curve obtained by mapping
sensitivity versus specificity for all possible values of the cut-off point
between pathology and healthy. Here, sensitivity (True Positives) was
defined as the probability of correctly classifying an individual as pathological, while specificity was the probability of correctly classifying
an individual as healthy asymptomatic (True Negative) (Zweig and
Campbell, 1993). The optimality criterion was given by:
26
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Fig. 2. Forest plot that presents the effect sizes for seven different parameters of walking, where a positive effect size represents higher variability of pathological
compared to the healthy asymptomatic group.
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minimum ((1

sensitivity ) 2 + (1

(2)

specificity )2)

3. Results

The optimum cut-off probability point, Popt , was obtained from Eq.
(2) as the point minimizing the Euclidean distance between the ROC
curve and the (1,1) coordinate on the ROC plane (Zweig and Campbell,
1993) - see Supp. Figures. 8–14 for details. Popt was then fed into Eq. (3),
obtained by reformulating the binary logistic regression function in Eq.
(1), in order to estimate the optimal threshold value, x opt , for a particular gait parameter.

x opt

(log
=

Popt
(1

Popt )

B0

)

When combined, a total of 85 studies from the current and original
review were considered for analysis, and 7 parameters were reported
across different pathological groups, resulting in a total of 147 ES values (Forest plot Fig. 2). The heterogeneity in this systematic evidence
was: I2 = 13.8%, with an average Cochrane’s Q of 198.5, which indicates excellent consistency across the publications reviewed. STV still
remained the most commonly reported parameter characterising MoV
(47 studies). Other frequently reported gait variability parameters were
variability of: a) stride length (23 studies), b) step length (22 studies), c)
swing time (13 studies), d) step time (12 studies), e) step width (7
studies), and f) dual limb support time (6 studies). The evaluated articles presented varying risk of bias and methodological quality. Mean
quality score was 13.38 ± 1.54 (range 10–17) for an ideal of 18. The
summary of the methodological score for each question and studies is
provided in Supp. Table 2. Unfortunately, only 45% of the included
studies used 50 or more steps in their analysis, which might be required
for reliable assessment of gait variability (König et al., 2014a).
Since 2014 when the previous review was conducted, nine additional
studies included STV in their trials, an increase of ∼24%, hence necessitating an update of the reported thresholds between healthy
asymptomatic and pathological variability. In the current study, we
evaluated the higher bound of physiological STV to be 2.34%, which is
0.26% lower than the estimate in the original review. The delta method
was then employed to identify the standard error in the likelihood estimates as ± 0.21%. The corresponding 95% confidence intervals
(95%CIs) for the upper thresholds of physiological stride time variability
were thus estimated as 1.92–2.76% (2 SDs above and below the mean).
Similar to STV, the optimal thresholds and subsequently the likelihood
estimates were also evaluated for the other commonly reported gait
parameters (Table 1). All comparisons had positive effect sizes (stride
time (0.75 ± 0.09), stride length (0.59 ± 0.11), step length
(0.82 ± 0.15), swing time (0.34 ± 0.11), step time (0.83 ± 0.20) and
dual limb support time (0.42 ± 0.27)), with the upper thresholds discriminating healthy asymptomatic from pathological gait, mostly ranging from approximately 2–6%, except step width variability with an ES
= −0.21 ± 0.18 and threshold of 15.9%. Furthermore, the most
commonly reported parameters, variability of stride time (N = 47) and
length (N = 23) were both highly significant (p < 0.01), while also
displaying the lowest Bayes Factor (< 1.4 e-4, see Supp. Table 3). Finally, the funnel plot (Fig. 3) of our data reveal asymmetrical distribution
towards positive ES due to possible reporting bias (reduced likelihood of
studies being published that report negative or no ESs).

(3)

B1

2.4. Probabilistic thresholds
Optimum separation between healthy asymptomatic and pathological motor performance for any physiological parameter (in our case
gait variability) will approach the “true value”, only when estimated
using a sufficiently large number of clinical trials with adequate sample
of healthy and pathological participants. Such a measure can only be
informative when the mean is reported together with its standard error,
hence providing the basis for confidence levels (or uncertainty) to be
evaluated (Altman and Bland, 2005). In the present study, the standard
error (SE) was estimated as probability boundaries (See Supp. Figures.
15–21) of the evaluated optimal threshold ( x opt ) via Eqns. 1 – 3, which
then provided a more systematic and reliable estimate of the window of
healthy physiological gait performance. SEs were evaluated using the
Delta Method involving a first-order Taylor approximation (Venables
and Ripley, 2010), which is given by:

SE (xopt ) =

[a b] *

var (B0 ) cov (B0, B1 )
*
cov (B0, B1 )
var (B1)

a
b

(4)

where

a=
b=

xopt
B0
xopt
B1

=
=

1
B1
xopt
B1

All analyses were conducted in Matlab (v2016b, The Mathworks
Inc., USA) and R (v3.4.1, The R Foundation for Statistical Computing,
Austria).
2.4.1. Case study
Experimental approach to demonstrate the application of optimal
thresholds in the clinical context.
In an attempt to demonstrate how the optimum thresholds can be
used to provide rapid and robust indications on healthy versus pathological gait performance, we exemplarily applied the synthesised evidence to preliminary movement data from a retrospective case-control
study. Twenty elderly volunteers including 10 patients with PD (PwPD)
with a mean(SD) age of 59(6)years, height 173.9(4.6)cm and weight
75.5(9.4)kg, as well as 10 healthy controls 65(11)years, height
165.6(5.3)cm and weight 61.7(8.4)kg were recruited. All participants
provided written, informed consent approved by the local ethics committee (registration number: 2015-00141) prior to participation. The
participants were requested to walk continuously in a path shaped as an
"8" in the laboratory for ten minutes at their own self-selected walking
speed (König et al., 2014a) while 3D kinematics of both feet from the
straight line walking (reflective markers placed on the calcaneus of each
foot) were only recorded using optical motion capture (VICON, OMG
Ltd, UK). PwPD were on their normal dopaminergic prescriptions at the
time of measurement. The median cohort score using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS III) while off medication was
38 (range 24–61) and while on medication was 22.5 (range 6–40).

3.1. Schematic representation of optimal thresholds data using radar plots
The patients suffering from basal ganglia disorders (Parkinson’s as
well as Huntington’s disease - Fig. 4b in red, please see figure caption
for details on the radar plot representation) had larger variabilities than
their asymptomatic counterparts (displayed Fig. 4a–f solid line in
green) in all the reported parameters, which were also outside the
higher bound of threshold (Fig. 4a–f green bars on axes). In contrast,
patients with cognitive disorders (e.g. Alzheimer’s disease or Mild
cognitive disorder - Fig. 4c in red) exhibited larger levels (in comparison to the asymptomatic group) for only the temporal variability
parameters. Finally, patients suffering from global disorders (e.g. Multiple sclerosis Fig. 4d.) also suffered from asymmetry issues (than the
asymptomatic group) as depicted with larger variability in both step
length and time.
3.2. Schematic representation benchmarking the data from the case study
with optimal thresholds using radar plots
Finally, Fig. 4e–f illustrate the results of the retrospective case
control study with patients suffering from Parkinson’s disease denoted
28
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Table 1
Effect size statistics including the z-test across all seven walking parameters, optimum thresholds and probabilistic levels (represented with Standard Errors) calculated at 50% dose levels.
Stride time
variability
No of Studies
Mean effect size [Hedge’s g]
Mean standard error of the
effect size [se]
Z-test
Optimum threshold (%CV)
Standard Error (%CV)
Specificity
Sensitivity
PwPD (n = 10)
Mean (SD)
HC (n = 10)
Mean (SD)

Stride length
variability

Step length
variability

Swing time
variability

Step time
variability

Step width
variability

Dual limb support time
variability

Meta - analytic data
47
23
0.75
0.59
± 0.09
± 0.11

22
0.82
± 0.15

13
0.34
± 0.11

12
0.83
± 0.20

7
−0.21
± 0.18

6
0.42
± 0.27

8.43
2.34
± 0.21
0.75
0.75

5.28
3.34
± 0.84
0.73
0.82

3.05
2.94
± 0.60
0.54
0.85

4.22
3.35
± 0.23
0.92
0.92

−1.17
15.87
± 1.86
1.00
0.86

1.58
6.08
± 2.83
0.67
0.83

Case study data (in %CV)
2.88 (1.52) 3.61 (1.29)

4.02 (1.71)

3.69 (2.34)

3.64 (2.08)

30.11 (12.46)

10.52 (5.01)

1.76 (0.57)

2.30 (0.45)

1.73 (0.36)

2.81 (1.66)

23.74 (6.53)

5.78 (0.97)

5.40
2.99
± 0.37
0.83
0.87

2.08 (0.50)

Mathiassen, 2012; Bryant et al., 2011). Despite this overwhelming
evidence, there has been limited uptake of MoV in clinical settings.
Contemporary reports (König et al., 2014a; Hausdorff, 2005; König
et al., 2016b; Dingwell and Cusumano, 2000) suggest that primary
reasons for such a discrepancy are: i) a lack of understanding and
misconceptions associated with MoV - e.g. MoV might represent error,
but is also associated with adaptability (Schmidt, 2003; Lipsitz and
Goldberger, 1992), ii) a subjective bias together with an arbitrary
choice of parameters, and iii) the general requirement for dedicated
measurements during extended periods of walking to effectively estimate MoV (König et al., 2014a). Despite the use of 4- and 6-minute
walk tests in clinical settings, the continued lack of comprehensive
assessment of gait quality suggests an opportunity missed, and perhaps
a disadvantage to both the individual patient and the health care
system. The evidence from this systematic review of the literature
clearly suggests that MoV is able to quantify gait quality, furthermore
the probabilistic analysis revealed an optimum threshold between
healthy asymptomatic and pathological gait patterns. As such, there is
potential added value of complementing standard clinical assessments
with the evaluation of MoV as a relevant movement biomarker for
identifying subjects with early signs of disease, but also in monitoring
adaptations after therapy. One of the principal challenges hindering the
uptake of MoV has been the need to collate the wealth of diverse literature, and provide a clear understanding of the healthy physiological
levels of variability during walking. This study has therefore directly
provided numerical evidence on healthy physiological movement performance, suggesting that locomotor tasks within populations suffering
from neurological disorders might be distinctly regulated from their
healthy asymptomatic counterparts (König et al., 2016a; Hausdorff,
2005; Stergiou and Decker, 2011).
A previous literature-based meta-analysis that investigated STV,
provided optimum thresholds for establishing the limits between
healthy asymptomatic and pathological task performance (König et al.,
2016b). Due to the lack of both large-scale as well as long-term assessments, this numerical evidence was plausibly subject to change with
new literature appearing. A preliminary search gauged and confirmed
the existence of substantial new evidence, which therefore necessitated
this review update (Garner et al., 2016). To accommodate such
changes, a probabilistic approach to evaluate the boundaries for
healthy performance in walking behaviour was considered within this
updated review. The CI of the upper threshold of 2.34 %CV ranged from
1.92 to 2.76 %CV, and provides a robust probabilistic estimate for
handling any new evidence on STV. An STV larger than this threshold,
and certainly one exceeding the CI’s upper boundary, indicates an
overall inability to maintain temporal consistency of foot placement,

Fig. 3. Publication bias demonstrated using funnel plots.

with red lines. The retrospective case control study revealed that PwPD
showed increased average gait variability compared to their healthy
counterparts within the case study (displayed in blue solid line), consistent with the systematic review data. The pooled mean of all the gait
variability parameters for controls within the case study were within
the derived window for healthy physiological gait performance (as
obtained from the meta-analytic investigation here and presented in
Table 1 and overlaid on the radial plot in green solid line – Fig. 4a–f),
while the mean of the PwPD cohort consistently lay outside the upper
thresholds of the optimal window (as indicated by the green bars on
each axes Fig. 4a–f). Fig. 4f also provides gait variability parameters for
each individual (dashed lines) patient (as well as participant) assessed
within the case study with the optimally identified thresholds (in green)
for comparison.
4. Discussion
Movement variability is an important characteristic that may represent both redundancy and adaptability of human task performance
(Hausdorff, 2005; Stergiou and Decker, 2011; Latash et al., 2002).
Recent investigations clearly demonstrate that MoV is sensitive to
adaptations, including learning new skills (Sternad, 2018; Wu et al.,
2014), the onset of movement disorders (König et al., 2016a; Hausdorff
et al., 2001; König et al., 2016b; Webster et al., 2006) and response to
therapies (Stergiou et al., 2006; Henderson et al., 2013; Srinivasan and
29
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Fig. 4. Radar plots allow cross fertilization of optimum windows (green bars on axes), including both lower and upper thresholds of all 7 signatures for rapid
determination of movement related deficit. Fig. 4a. Here, the overall mean of the commonly reported gait variability parameters for healthy asymptomatic controls
obtained from the studies included within the systematic review provides the baseline, and is depicted with green solid line. The optimum windows for the gait
characteristics (depicted as green bars on the different axes on the radial plot) are formed using the optimum threshold (higher bound) identified from the logistic
regression procedure and lowest observed group value for the asymptomatic subjects (lower bound). Fig. 4b. – d. Radar plots illustrating patients grouped according
to the pathology from the studies included in the meta-analysis (solid red line). b. The overall mean of patients suffering from basal ganglia group (red), c. The overall
mean of patients belonging to the cognitive group (red). d. The overall mean global group (red). Fig. 4e & f. Radar plots illustrating patients with Parkinson’s Disease
from the retrospective case study (solid red line). e. Parameter variables extracted from the retrospective case-study allow a comparison against PwPDs and healthy
older adults (solid blue line). All values outside of the optimum windows indicate movement deficits. In this case not only did the mean of the PwPDs have higher
levels of variability compared to the healthy controls, but the values were also consistently outside the upper thresholds of the optimal window. f. Average
retrospective case-study data on PwPDs (red solid line) and healthy older adults (blue solid line), individual retrospective case-study data on PwPDs (red dashed
lines) and healthy older adults (blue dashed lines). All values are presented in standardized or z-scores. The solid axes on each of the radial plot, in grey and radiating
from the center of the plot range from -3.5 to 3.5 z-scores. The horizontal axis on the right-hand side displaying variability (Var) of stride length (StrideL) followed by
(in a clockwise manner) step length (StepL), step time (StepT), swing time (SwingT), dual limb support time (DLS-T), stride time (StrideT), and step width (StepW),
represent the 7 signatures considered within the study.

such that walking performance might, in general, be closer to the limits
of stability (Bruijn and van Dieen, 2018; König et al., 2016a). Specifically, an inter-cycle STV larger than the threshold might lead to inconsistency between swing and stance phases of gait making it difficult
to maintain the CoM of the body within the base of support across
cycles. Such an estimate therefore provides a meaningful threshold for
objectively assessing STV and highlighting its value for clinical uptake
for the purposes of screening individuals that might suffer from
movement impairments.
In the interest of translation to clinical settings, an important
question is: “Does STV - the single most commonly used parameter of
MoV - have the necessary attributes to qualify as a gait biomarker for
detecting movement disorders? Here, Hausdorff (2005) has proposed
that for MoV to be used as a biomarker, its reliability, accuracy, sensitivity and clinical utility (time- and cost-effectiveness) should all be

established, or an optimal trade-off between all these attributes should
be found. The duration of walking trials has a substantial effect on the
reliability of assessing kinematic variability (Owings and Grabiner,
2003), but STV has also been shown to be modestly reliable with 50
steps, resulting in an inter-day test-retest variability of ∼13% (König
et al., 2014a). This systematic review revealed that STV had a large
effect size with the lowest standard errors for discriminating healthy
asymptomatic vs. pathological performance (Table 1). Furthermore, the
logistic regression model based on population data revealed that there
is clearly a high level of sensitivity and specificity (75%) for using STV
alone to identify movement disorders, proving its predictive capability
(Table 1). Benchmarking demonstrated robust levels for higher bounds
of unstable walking performance, providing the much-needed impetus
for the practical uptake of STV in clinical settings towards accurately
identifying individuals that suffer from movement impairments.
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Finally, although direct evidence of clinical utility of STV remains
lacking, the metric is seemingly well-accepted and incorporated in
many clinical trials as a primary (Lord et al., 2011) or secondary outcome measure (Zweig and Campbell, 1993; Henderson et al., 2013).
Notably, a Phase II clinical trial has recently used step time variability
as a surrogate marker to investigate gait stability and fall risk in PwPD
(Henderson et al., 2016). Finally, the accessibility of this parameter
from wearable technologies clearly promotes STV as a promising signature for assessing movement rhythmicity.
Wearable technologies provide easy access to MoV indicators, such
as STV, for patients in real-world or ecologically valid scenarios and
therefore deliver a viable and cost-effective means for population-wide
screening, but also for personalized monitoring of patients over extended periods. With a complete system that includes wearables and a
clear interpretation of gait quality, it is possible to assess large-scale
movement data (large sample sizes) over a long-term follow-up (multiple assessments from every individual). Subtle differences during repetitive tasks can then be recognized in an unbiased and rapid manner
and be combined with the clinical status of the individual to provide
close tracking of neuro-muscular performance. Here, the potential of
MoV, especially STV, to identify motor quality in clinical populations
has been well recognized (Kovacs, 2005; Song and Geyer, 2017; MoeNilssen et al., 2010; Stergiou and Decker, 2011). However, STV as well
as other parameters will need to be quantified and generalized across
populations in order to establish their association with other signatures
(or features) of gait quality. While the methodological challenges associated with the quantitative assessment of various attributes of reliability and accuracy in MoV (König et al., 2014a, 2014b; Beauchet
et al., 2009) have now mostly been resolved, epidemiological research
in ecologically valid settings is still required before elevated clinical
uptake can be realised.
While gait variability metrics such as STV are clearly quantifiable
indicators of neural control of movement, it is hard to believe that just
one parameter can independently characterize age and pathology related motor control impairments. By focusing predominantly on STV,
movement scientists and clinicians might well under-estimate the
complexity of gait control. Recent evidence indicates that multiple
signatures are modulated differently by age (Rosso et al., 2014), pathology (Moe-Nilssen et al., 2010; Takakusaki, 2013), walking speed
(Frenkel-Toledo et al., 2005), gender (Hughes-Oliver et al., 2018), but
more importantly also by complex interactions between one or more of
these factors (e.g. for age and walking speed see (Callisaya et al., 2010;
Helbostad and Moe-Nilssen, 2003)). Although we did not observe a
considerable effect of age on the overall effect size (or on stride time
variability undertaken in separate subgroup analyses - Supplementary
Tables 4 & 5), the modulatory effects of walking speed or gender could
not be explored within this meta-analysis due to the lack of availability
of data within the original studies. Despite this discrepancy, the metaanalysis clearly provides evidence on optimal boundaries for variability
of multiple commonly identified spatio-temporal parameters.
Of all the parameters reported, step width variability was the only
metric to exhibit reduced levels of variability in pathological populations compared to healthy asymptomatic individuals. This result is
consistent with the original systematic review (König et al., 2016b) and
coherent to previous findings that diminished step width variability is
linked to poor balance and fall risk (Maki, 1997). On the neuromotor
level, this observation plausibly indicates tightening control in one dimension at the expense of another. The significance of this finding
however, needs further exploration and should be interpreted with
caution, especially in the context of its dynamic interplay with both
centre of mass kinematics (Arvin et al., 2018; Wang and Srinivasan,
2014), but also STV during task execution (Bauby and Kuo, 2000). In
fact, variability in step width reflects the regulation of the body’s base
of support in order to maintain balance in the medio-lateral direction
during walking. Biomechanically, modifications to step width (e.g. extending the lateral margins of the base of support – see Bruijn and van

Dieen, 2018; Wang and Srinivasan, 2014; König Ignasiak et al., 2019)
and/or double limb support time (extended time period during which
the projected CoM is within the base of support) might influence our
balance during walking (Moe-Nilssen et al., 2010; Rosenblatt et al.,
2014; Galna et al., 2013; Owings and Grabiner, 2004; Gabell and
Nayak, 1984). Moreover, step width might be regulated on a cycle-tocycle basis and is intricately related to the walking speed (Helbostad
and Moe-Nilssen, 2003; Stimpson et al., 2018), the kinematic state of
the CoM (Bruijn and van Dieen, 2018), but also the energy requirements (Donelan et al., 2001, 2004) as well as other environmental
constraints. Although step width as well as dual limb support time have
been suggested to reflect balance control (Bruijn and van Dieen, 2018;
Wang and Srinivasan, 2014; König Ignasiak et al., 2019), the number of
studies that reported step width variability (as well as dual limb support
time variability) are approximately 9 times lower than those reporting
STV. Despite widespread access to wearable technologies that allow the
assessment of temporal parameters, their inability to assess spatial
parameters such as step width is one of, if not the reason for this disproportionality. Interestingly, variability of double-support time (a
temporal parameter), conventionally associated with balance control,
actually demonstrated a positive overall effect size, it might represent a
different sub-feature than the variability of step width (a spatial parameter), within the qualitative domain of balance control. Overall, the
role of neuromotor control on step width variability (and dual limb
support time variability) in older and pathological populations needs
further investigation.
The hypothesis of dynamic interplay between movement or gait
signatures (but also relevant as independent domains), such as that
between rhythmicity and balance control, highlights the need for comprehensive assessment of movement performance in future over the
more conservative and commonplace subjective approach of pre-selecting parameters in an arbitrary manner. Here, we support the necessity of assessing a family (for similar approach please also see (Lord
et al., 2013)) of gait signatures including but not limited to rhythmicity,
balance, coordination, regularity (the predictability of movement),
asymmetry (motor and/or physical symptom leading to discrepancy
between parameters from two limbs) and obstacle avoidance. In fact,
results presented here provide preliminary evidence that movement
disorders affecting different regions of the brain (i.e. Parkinson’s vs.
Alzheimer’s disease) might influence different signatures (cf. Fig. 4b vs.
c). Such representation therefore clearly indicates how presenting
boundaries for multiple parameters enables rapid determination of a
particular motor deficit, but also allows comparison across different
disease groups. In future an operational model, which provides an unbiased statistical/data-lean presentation to extract the most important
signatures, would be a preferred approach that will allow clinicians to
characterize complex distinctive walking behaviours in both healthy
asymptomatic and pathological individuals. Such an approach could
incorporate multivariate methods to rank the important signatures from
kinematic data, while simultaneously allowing the identification of
interplay between the signatures. Consequently, it would also make way
for multivariate classification models using population based optimal
estimates, which until now has not been available. Establishing and
benchmarking movement signatures with population based optimal estimates
as has been undertaken in this review will allow generalized estimates of
MoV to provide scalable and unbiased information on movement quality.
Finally, we have reported a preliminary approach to characterize
motor impairments in subjects with movement disorders based on population-based evidence derived from the meta-analysis. The usage of
this approach has been demonstrated in an exemplary case study
comprising PwPD (Fig. 4e–f). In general, captured and pre-processed 3D
kinematics of patients (using e.g. optical motion capture or wearable
inertial sensors), thus allows easy access to an individual’s movement
signatures. The boundaries identified within the meta-analysis and
presented within the case study (Fig. 4e–f) now provide an easy and
accessible manner to benchmark such movement signatures against data
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from 85 studies containing 2409 patients and 2523 healthy asymptomatic controls (Table 1), e.g. 1.92–2.76%CV as uncertainty for the
upper threshold of 2.34 %CV for STV, such that we have an effective
and rapid screening of movement performance. Further studies are
necessary to explore the broader utility and potential biases of our
approach (utilizing optimum thresholds obtained through meta‐analyses based on aggregate data to benchmark individual’s movement
quality might not be always straightforward). Nevertheless, our robust
meta-analytic approach will allow the uptake of objective metrics on
signatures within clinical information, a concept that is extremely important, but is not well appreciated until now (Lord et al., 2013).
Overall, when viewed from a human sensory motor control perspective, a neurophysiological approach that collates all available evidence-based clinical information in a statistical model, would bridge
the gap in knowledge between currently dominant bipedal walking
(e.g. (Bauby and Kuo, 2000)) and neuroanatomical (e.g (Takakusaki,
2013).) models. In the context of clinical decision-making, a gait hypermodel (an integrative model that synergizes knowledge from multiple models) that combines a neurophysiological model (experimentally validated and therefore physiologically representative, but
generally in laboratory settings) with a statistical model (populationbased using rapid clinical tests and therefore providing comprehensive
and ecologically valid evidence) offers the ability to identify biomarkers
and thereby objectively track the state of a pathology (monitoring) and
track its progression (prognostic). In addition, such a gait hypermodel
opens perspectives for estimating susceptibility (risk), e.g. in the prediction of an individual’s risk of falling (BEST, 2016). An additional
benefit would be the exploration of task performance in scenarios that
might be unethical or harmful through statistical perturbation via
probabilistic techniques such as Monte Carlo methods.
Information on MoV has obvious relevance for the deeper understanding of movement control mechanisms and has been extensively
investigated in both healthy asymptomatic and pathological cohorts.
Clinical interest in the use of MoV as a biomarker for identifying pathological movement status has increased considerably in recent years,
as evident through the publication of 21 relevant studies in 4 years
compared to 64 in the previous 34 years. It now seems plausible that
quantitative motor performance data (also in the form of pooled population information available through this review) can be utilized for
developing gait hypermodels (such as the one proposed in this paper)
with a vision for benchmarking behaviour, developing biomarkers and
understanding neuro-adaptive behaviour of aged and pathological populations.
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